<html>
<head>PUBMED IDs for CDT2</head>
<body bgcolor='#C5F0F2'><h1>CDT2</h1><a href='https://pubmed.ncbi.nlm.nih.gov/17085480/'>DTL/CDT2 is essential for both CDT1 regulation and the early G2/M checkpoint.</a> November 7  2006<br><a href='https://pubmed.ncbi.nlm.nih.gov/18213392/'>Transcriptional regulation of an evolutionary conserved intergenic region of CDT2-INTS7.</a> January 24  2008<br><a href='https://pubmed.ncbi.nlm.nih.gov/21822310/'>1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma.</a> April 25  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/21981919/'>A genome-wide screen identifies p97 as an essential regulator of DNA damage-dependent CDT1 destruction.</a> December 21  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/23109433/'>CRL4(CDT2) targets CHK1 for PCNA-independent destruction.</a> February 22  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/23478441/'>Regulation of the CRL4(Cdt2) ubiquitin ligase and cell-cycle exit by the SCF(Fbxo11) ubiquitin ligase.</a> May 25  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/23995842/'>Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer.</a> December 16  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/25008066/'>Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applications.</a> May 15  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25411249/'>CDK1-dependent inhibition of the E3 ubiquitin ligase CRL4CDT2 ensures robust transition from S Phase to Mitosis.</a> April 8  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/27323328/'>Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing.</a> June 7  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/27333051/'>Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.</a> February 15  2016<br></body></html>
